Regeneron Pharma Live Stock Price Today, Share Analysis and Chart

Name: Regeneron Pharmaceuticals, Inc.: Is Infosys Ltd. worth buying?
Item: Regeneron Pharmaceuticals, Inc.
Rating: 2.007416625
Author: Trendlyne DVM scores

Await Turnaround

about

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet ag...

745.77 -0.84 (-0.11%)

56.51% Gain from 52W Low

438.1K

XNAS Volume

XNAS 13 Mar, 2026 5:30 PM (EDT)

Low Financial Strength

33.3 / 100

Mid Valuation

42.2 / 100

Technically Neutral

51.8 / 100

Await Turnaround These stocks have poor financials and average valuation and momentum. Investors should be cautious about these stocks View Similar Embed DVM

873

1Yr Price target upside is 17%

27 analysts

Regeneron Pharma Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Regeneron Pharma Live Stock Price Today, Share Analysis and Chart

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet ag...

56.51% Gain from 52W Low

SWOT Analysis

Regeneron Pharma Live Price Chart